[go: up one dir, main page]

NI201000209A - Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - Google Patents

Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato

Info

Publication number
NI201000209A
NI201000209A NI201000209A NI201000209A NI201000209A NI 201000209 A NI201000209 A NI 201000209A NI 201000209 A NI201000209 A NI 201000209A NI 201000209 A NI201000209 A NI 201000209A NI 201000209 A NI201000209 A NI 201000209A
Authority
NI
Nicaragua
Prior art keywords
enhancers
metabotropic glutamate
glutamate receptors
isoxazole derivatives
isoxazole
Prior art date
Application number
NI201000209A
Other languages
English (en)
Inventor
Cacciola Joseph
Empfield James
Folmer James
M Hunter Angela
Throner Scott
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of NI201000209A publication Critical patent/NI201000209A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/08—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
    • A61B17/083—Clips, e.g. resilient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/08—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
    • A61B17/085—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound with adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/10—Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/10—Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
    • A61B17/105—Wound clamp magazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de acuerdo con la Fórmula (I): en donde R1, R2, R3 y R4 son como están definido en la descripción, sales farmacéuticamente aceptables, métodos de elaboración, composiciones farmacéuticas conteniendolo y métodos de uso de los mismos.
NI201000209A 2008-06-06 2010-08-13 Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato NI201000209A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5948508P 2008-06-06 2008-06-06

Publications (1)

Publication Number Publication Date
NI201000209A true NI201000209A (es) 2012-11-07

Family

ID=41398335

Family Applications (3)

Application Number Title Priority Date Filing Date
NI201000209A NI201000209A (es) 2008-06-06 2010-08-13 Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
NI2010002092A NI201002092A (es) 2008-06-06 2010-12-06 Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato.
NI2010002091A NI201002091A (es) 2008-06-06 2010-12-06 Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato.

Family Applications After (2)

Application Number Title Priority Date Filing Date
NI2010002092A NI201002092A (es) 2008-06-06 2010-12-06 Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato.
NI2010002091A NI201002091A (es) 2008-06-06 2010-12-06 Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato.

Country Status (40)

Country Link
US (4) US7790760B2 (es)
EP (2) EP2772492B1 (es)
JP (2) JP5476371B2 (es)
KR (1) KR20110020797A (es)
CN (1) CN102105466B (es)
AR (1) AR072016A1 (es)
AU (1) AU2009255784B2 (es)
BR (1) BRPI0913585A2 (es)
CA (1) CA2726925A1 (es)
CL (1) CL2010001348A1 (es)
CO (1) CO6321239A2 (es)
CR (1) CR11826A (es)
CU (1) CU23883B1 (es)
CY (1) CY1115301T1 (es)
DK (1) DK2303872T3 (es)
DO (1) DOP2010000375A (es)
EA (2) EA018412B1 (es)
EC (1) ECSP10010662A (es)
ES (1) ES2469837T3 (es)
GT (1) GT201000342A (es)
HK (1) HK1201255A1 (es)
HN (1) HN2010002582A (es)
HR (1) HRP20140451T1 (es)
IL (1) IL209622A0 (es)
MX (1) MX2010012949A (es)
MY (1) MY156552A (es)
NI (3) NI201000209A (es)
NZ (1) NZ590344A (es)
PE (1) PE20110028A1 (es)
PL (1) PL2303872T3 (es)
PT (1) PT2303872E (es)
RS (1) RS53392B (es)
SA (1) SA109300358B1 (es)
SI (1) SI2303872T1 (es)
SV (1) SV2010003751A (es)
TW (3) TW201514173A (es)
UA (1) UA107649C2 (es)
UY (1) UY31870A (es)
WO (1) WO2009148403A1 (es)
ZA (1) ZA201008611B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
DE602008004794D1 (de) 2007-09-14 2011-03-10 Addex Pharmaceuticals Sa 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyridinyl-2'-one
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
SA109300358B1 (ar) * 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CN102186477B (zh) 2008-10-16 2013-07-17 奥梅-杨森制药有限公司 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010130422A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AR076861A1 (es) 2009-05-12 2011-07-13 Addex Pharma Sa Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
SMT201900545T1 (it) 2014-01-21 2019-11-13 Janssen Pharmaceutica Nv Combinazioni comprendenti modulatori allosterici positivi o agonisti ortosterici del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo
WO2015157187A1 (en) 2014-04-06 2015-10-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
KR101663662B1 (ko) * 2015-06-17 2016-10-14 한국과학기술연구원 대사성 글루타메이트 수용체 1에 활성을 지닌 신규 아릴 아이소옥사졸 유도체
US20170145002A1 (en) * 2015-11-25 2017-05-25 Astrazeneca Ab Deuterated isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE620654C (de) 1933-04-29 1935-10-24 Smith & Sons Ltd S Geschwindigkeitsanzeiger
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (fr) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. Derive de 3-methylenisoindolin-1-one
TW219935B (es) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
AU1618697A (en) * 1996-02-06 1997-08-28 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
CA2291630A1 (en) 1997-05-30 1998-12-03 Tetsutaro Niizato Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same
JP2001524468A (ja) 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
DE60129210T2 (de) * 2000-02-29 2008-03-20 Mitsubishi Pharma Corp. Zyklische amid-derivate
KR20030059084A (ko) 2000-07-31 2003-07-07 스미스크라인 비참 피.엘.시. 카르복사미드 화합물 및 이것의 사람 11ｃｂｙ 수용체의길항제로서의 용도
WO2003016254A1 (en) 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
AU2003226927A1 (en) 2002-04-09 2003-10-27 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
US7507836B2 (en) 2003-03-26 2009-03-24 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US7129260B2 (en) * 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
US20070135485A1 (en) 2003-10-22 2007-06-14 Gillig James R Novel mch receptor antagonists
WO2005074643A2 (en) 2004-01-30 2005-08-18 Smithkline Beecham Corporation Benzamide compounds useful as rock inhibitors
UA82435C2 (uk) 2004-02-18 2008-04-10 Astrazeneca Ab Конденсовані гетероциклічні сполуки та їх застосування як метаботропних антагоністів рецепторів глутамату, фармацевтична композиція на їх основі
EP1726585A4 (en) 2004-03-05 2009-07-15 Banyu Pharma Co Ltd DIARYLSUBSTITUTED FIVE-GLOSS HETEROCYCLUS DERIVAT
CN102558082B (zh) 2004-03-05 2015-09-30 日产化学工业株式会社 异噁唑啉取代苯甲酰胺化合物的制备中间体
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
CN101048157A (zh) 2004-10-25 2007-10-03 默克公司 代谢型谷氨酸受体的杂环二氢茚酮增强剂
US7960417B2 (en) 2005-02-24 2011-06-14 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
NZ564254A (en) 2005-05-18 2011-04-29 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
TW200728277A (en) 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
JP2009509921A (ja) * 2005-08-12 2009-03-12 アストラゼネカ アクチボラグ 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
CN101273040B (zh) 2005-09-27 2011-11-09 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的*二唑基吡唑并嘧啶类化合物
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
SA109300358B1 (ar) * 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون

Also Published As

Publication number Publication date
GT201000342A (es) 2015-02-16
UA107649C2 (uk) 2015-02-10
UY31870A (es) 2010-01-29
EA201300342A1 (ru) 2014-02-28
US20100317662A1 (en) 2010-12-16
WO2009148403A1 (en) 2009-12-10
TWI382027B (zh) 2013-01-11
JP2014114312A (ja) 2014-06-26
US7888353B2 (en) 2011-02-15
EP2303872A1 (en) 2011-04-06
EA201001724A1 (ru) 2011-08-30
US20090306158A1 (en) 2009-12-10
AU2009255784A1 (en) 2009-12-10
NZ590344A (en) 2012-07-27
MX2010012949A (es) 2010-12-15
SV2010003751A (es) 2011-04-14
TW201247658A (en) 2012-12-01
SI2303872T1 (sl) 2014-06-30
JP2011522816A (ja) 2011-08-04
US20100022545A1 (en) 2010-01-28
IL209622A0 (en) 2011-02-28
CN102105466B (zh) 2014-10-15
MY156552A (en) 2016-02-26
ECSP10010662A (es) 2011-01-31
CN102105466A (zh) 2011-06-22
ES2469837T3 (es) 2014-06-20
CL2010001348A1 (es) 2011-03-25
RS53392B (sr) 2014-10-31
PL2303872T3 (pl) 2014-08-29
EA018412B1 (ru) 2013-07-30
DOP2010000375A (es) 2010-12-31
KR20110020797A (ko) 2011-03-03
EP2303872B1 (en) 2014-04-16
EP2772492A1 (en) 2014-09-03
US7790760B2 (en) 2010-09-07
CA2726925A1 (en) 2009-12-10
HN2010002582A (es) 2012-08-27
US8148372B2 (en) 2012-04-03
CR11826A (es) 2011-02-04
NI201002091A (es) 2012-11-07
HK1201255A1 (en) 2015-08-28
HK1155744A1 (en) 2012-05-25
JP5476371B2 (ja) 2014-04-23
PT2303872E (pt) 2014-06-23
NI201002092A (es) 2012-11-07
SA109300358B1 (ar) 2012-11-03
US7781434B2 (en) 2010-08-24
ZA201008611B (en) 2012-05-30
US20100324044A1 (en) 2010-12-23
JP5815765B2 (ja) 2015-11-17
TWI477499B (zh) 2015-03-21
HRP20140451T1 (hr) 2014-08-01
CU20100238A7 (es) 2011-11-15
EP2772492B1 (en) 2016-08-17
CY1115301T1 (el) 2017-01-04
TW201002699A (en) 2010-01-16
BRPI0913585A2 (pt) 2015-10-27
EP2303872A4 (en) 2012-03-21
CU23883B1 (es) 2013-04-19
CO6321239A2 (es) 2011-09-20
AR072016A1 (es) 2010-07-28
DK2303872T3 (da) 2014-06-16
PE20110028A1 (es) 2011-02-11
TW201514173A (zh) 2015-04-16
AU2009255784B2 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
NI201000209A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
UY32296A (es) Nuevos compuestos
DOP2010000047A (es) Compuestos de pirazol y su uso como inhibidores de raf
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
GT201300236A (es) Derivados de pirrolo (2,3-d) pirimidina como inhibidores de quinasa relacionados con tropomiosina
CR10148A (es) Derivados de las benzamidas y heteroarenos
UY31639A1 (es) Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
ECSP13012788A (es) Derivados de biciclo[3,2,1]octilamida y sus usos
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY29988A1 (es) Compuestos de oxazolidinona y su uso como potenciadores del receptor metabotrópico de glutamato
ECSP099565A (es) Compuesto de 2-amino pirimidina
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
BR112014017735A8 (pt) Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
UY28737A1 (es) Compuestos farmacéuticamente activos
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
ECSP11011053A (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones